Add BrightSurf on Google Email

JMIR Publications’ JMIR Bioinformatics and Biotechnology invites submissions on Bridging Data, AI, and Innovation to Transform Health

The journal explores the convergence of computational biology, artificial intelligence, and healthcare innovation, with a focus on precision medicine and enhanced patient care. Submissions are accepted from researchers, clinicians, and technologists on topics such as AI in medicine, computational genomics, and drug discovery.

Why Triceratops has such a big nose

Researchers from the University of Tokyo used CT scans to study Triceratops' nasal anatomy, revealing a specialized structure called a respiratory turbinate. This unique feature helped regulate temperature and moisture levels in the dinosaur's large skull.

SourceUniversity of Tokyo·JournalThe Anatomical Record·TypeExperimental study·DateFeb 17, 2026

No increased risk of rectal cancer in ulcerative proctitis

A new study published in Gastroenterology has investigated the link between ulcerative proctitis and rectal cancer, revealing no increased risk in patients with isolated proctitis. The study followed nearly 16,000 people with ulcerative proctitis for over ten years, finding a low incidence of rectal cancer and precancerous lesions.

SourceKarolinska Institutet·JournalGastroenterology·DateFeb 3, 2026

A CNIO study completely eliminates pancreatic tumors in mice without resistance developing

A study published in PNAS successfully eliminated pancreatic tumours in mice completely and durably, with no significant side effects. The treatment, combining three molecular targets, induced robust regression of experimental PDACs without causing tumor resistance.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateFeb 3, 2026

A systematic review organises available omics data on pituitary tumours

A recent systematic review has compiled and catalogued publicly available omics data on pituitary tumours, highlighting the need for standardisation and clinical annotation. The resulting catalogue facilitates the reuse of data for future research projects and precision medicine initiatives.

SourceGermans Trias i Pujol Research Institute·JournalMachine Learning and Knowledge Extraction·TypeSystematic review·DateFeb 2, 2026

Cancer incidence and mortality with aspirin in older adults

A recent study found that low-dose aspirin use was not associated with incident cancer incidence in older adults, contrary to previous findings. However, the study revealed a significant elevation in cancer mortality risk during the randomized clinical trial period, which did not persist after the trial ended.

SourceJAMA Network·JournalJAMA Oncology·DateJan 29, 2026

Early recognition and surgical management key in necrotizing fasciitis of the head and neck

Early recognition and surgical management are crucial in treating necrotizing fasciitis of the head and neck, a rare but life-threatening soft tissue infection. The authors emphasize the urgent need for coordinated care, including immediate surgery, broad-spectrum antibiotics, and airway protection to reduce mortality rates.

SourceImpact Journals LLC·JournalOncoscience·TypeNews article·DateJan 29, 2026

Study identifies PARG as a new target to enhance chemotherapy in colorectal cancer

A study led by researchers from the Germans Trias i Pujol Research Institute has identified PARG as a new target to enhance chemotherapy in colorectal cancer. Inhibition of PARG significantly increases the cytotoxic effect of chemotherapy, leading to enhanced cell death and apoptosis in different colorectal cancer models.

SourceGermans Trias i Pujol Research Institute·JournalClinical and Translational Medicine·TypeExperimental study·DateJan 28, 2026

Treatment initiation is possible with a positive liquid biopsy in primary central nervous lymphoma patients with difficult-to-access lesions

Researchers successfully diagnosed and treated ten PCNSL patients using liquid biopsy, detecting hotspot MYD88 L265P mutations in circulating tumor DNA. This method offers a reliable alternative to surgical biopsies for patients with difficult-to-access lesions or frailty, enabling timely treatment initiation.

SourceNiigata University·JournalNeuro-Oncology Advances·DateJan 27, 2026

An AI to predict the risk of cancer metastases

Scientists at UNIGE created an AI tool called MangroveGS that can accurately predict the risk of cancer metastasis and recurrence. The algorithm uses gene expression signatures from colon cancer cells to identify key factors influencing metastatic potential, paving the way for more precise care and discovery of new therapeutic targets.

SourceUniversité de Genève·JournalCell Reports·TypeNews article·DateJan 22, 2026

Leading cancer deaths in people younger than 50 years

Cancer mortality rates have decreased for breast cancer and leukemia, despite increasing incidence, while colorectal cancer has become the leading cause of death among US young adults. Colorectal cancer surpasses lung, breast, and prostate cancers as the leading cancer-related death in people under 50 years old.

SourceJAMA Network·JournalJAMA·DateJan 22, 2026

National Foundation for Cancer Research CEO Sujuan Ba Named One of OncoDaily’s 100 Most Influential Oncology CEOs of 2025

Sujuan Ba, CEO of the National Foundation for Cancer Research, has been recognized as one of OncoDaily's 100 Most Influential CEOs in Oncology in 2025. Under her leadership, NFCR has strengthened its role as a strategic accelerator of cancer research, supporting innovative science and fostering cross-sector collaboration.

Korea University researchers discover that cholesterol-lowering drug can overcome chemotherapy resistance in triple-negative breast cancer

Researchers found that pitavastatin directly inhibits the anti-apoptotic protein Mcl-1, a key driver of survival and resistance in TNBC cells. The study showed pitavastatin effectively eliminates cancer stem-like cell populations and reduces tumor growth, angiogenesis, and lung metastasis.

SourceKorea University College of Medicine·JournalExperimental Hematology and Oncology·TypeExperimental study·DateJan 7, 2026

Clostridioides difficile: A suspected pro-carcinogenic bacterium for gastrointestinal tumors

A recent review suggests that Clostridioides difficile infection may promote the development of gastrointestinal tumors, including colorectal cancer. The bacterium's toxins can cause damage to the epithelial cytoskeleton and induce inflammation, leading to chronic colitis and increased risk of CRC.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateDec 22, 2025

A new study explores why the same mutation in the BRAF gene leads to different therapeutic responses to its inhibitors in melanoma and colorectal cancer

A new study by researchers from the Germans Trias i Pujol Research Institute provides a comparative analysis of the impact of BRAF gene mutations in melanoma and colorectal cancer. The review highlights molecular, cellular, and tumour microenvironment factors that explain the therapeutic dichotomy between the two tumour types.

SourceGermans Trias i Pujol Research Institute·JournalBiochimica et Biophysica Acta·TypeLiterature review·DateDec 22, 2025

Results from IMMUNOMICS-VHIO platform’s first study demonstrate the efficacy of ultrasensitive liquid biopsy in predicting and monitoring immunotherapy response

Researchers have developed an ultrasensitive liquid biopsy platform to predict and monitor immunotherapy response in advanced cancer patients. The study shows that lower levels of circulating tumor DNA (ctDNA) at baseline are associated with better progression-free survival and overall survival.

SourceVall d'Hebron Institute of Oncology·JournalClinical Cancer Research·DateDec 17, 2025

Blood test may help identify which colon cancer patients benefit from NSAIDs

A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.

SourceAlliance for Clinical Trials in Oncology·JournalJAMA Oncology·TypeRandomized controlled/clinical trial·DateDec 15, 2025

Adding antibody treatment to chemo boosts outcomes for children with rare cancer

A phase two trial found that adding dinutuximab beta to chemotherapy improves the best objective response rate and overall survival time for children with relapsed or refractory neuroblastoma. The treatment resulted in a significant increase in patients' tumors shrinking after six cycles of treatment.

SourceUniversity of Birmingham·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateDec 12, 2025

NEJM Group launches NEJM Clinician

NEJM Clinician curates highly relevant clinical insights from over 150 peer-reviewed journals to give physicians clear guidance without the noise. The weekly publication delivers summaries and commentary in a concise, 30-minute read, helping healthcare providers stay informed and confident in their decisions.

SourceNEJM Group·JournalNew England Journal of Medicine·DateDec 8, 2025

Lower doses of immunotherapy for skin cancer give better results

A new study by researchers at Karolinska Institutet found that lower doses of approved immunotherapy drugs can give better results against tumours, while reducing side effects. The regimen with the lower dose of ipilimumab was more effective, with a higher proportion of patients responding to treatment and longer overall survival.

SourceKarolinska Institutet·JournalJNCI Journal of the National Cancer Institute·TypeObservational study·DateDec 7, 2025